AzurRx BioPharma Announces Two Abstracts Accepted for Presentation at the 2020 North American Cystic Fibrosis Virtual Conference
Abstracts to Focus on:
Results from Phase 2, Open-Label, Multicenter, 2x2 Cross-Over Trial to Assess Safety and Efficacy of MS1819 in Patients with Exocrine Pancreatic Insufficiency Due to Cystic Fibrosis
Best Enteric Capsule for Targeted Duodenal Delivery of Non-Porcine MS1819 Lipase Enzyme
NEW YORK, Sept. 15, 2020 (GLOBE NEWSWIRE) -- AzurRx BioPharma, Inc (NASDAQ:AZRX) (“AzurRx” or the “Company”), a company specializing in the development of non-systemic, recombinant therapies for gastrointestinal diseases, today announced that two abstracts have been accepted for presentation at the North American Cystic Fibrosis Conference (NACFC) to be held virtually October 7 – October 23, 2020. The abstracts will be showcased in the NACFC virtual poster gallery and electronically published as a supplement to Pediatric Pulmonology.
“We are pleased to present the results from the Phase 2 OPTION clinical trial demonstrating that the non-porcine MS1819 lipase is well-tolerated with no clinically significant safety signals at the 2g daily dose,” said James Sapirstein, President & CEO of AzurRx. “Furthermore, we have evaluated four different enteric capsules and identified the best suitable formulation for MS1819 that provides gastroprotection of enzyme content and delayed release into the duodenum. Our clinical program continues to advance, and we are determined to develop MS1819 as a safer alternative to porcine pancreatic enzyme replacement therapy (PERT), significantly reducing the pill burden of cystic fibrosis patients.”
Presentation Poster Details Below:
About AzurRx BioPharma, Inc.
For more information:
AzurRx BioPharma, Inc.
Investor Relations contact:
LifeSci Advisors, LLC.
How to Strategically Leverage New Connectivity Options